Literature DB >> 11882058

Epidemiological aspects of headache in a workplace setting and the impact on the economic loss.

P H M Pop1, C M Gierveld, H A M Karis, H G M Tiedink.   

Abstract

The objective of this study was to assess the epidemiological aspects of headache in a workplace setting and the economical impact. By sending a questionnaire to 1781 employees of a Dutch manufacturing company we tried to assess the prevalence of headache and headache subtype within this working place. Besides the personal view of each responder regarding his/her headache subtype, the International Headache Society (IHS) criteria were used to classify headaches on the basis of reported features. Moreover the missing labour days, as a result of headache, during the previous 4 weeks were measured, as well as the loss of productivity at the working place during an episode of headache; from this an estimate of the economic loss could be calculated. The response rate of the questionnaire was 60.8%. The lifetime prevalence of headache amongst the responders was 53.3%. Of these, 34.5% thought their headache was tension-type headache, 10.6% thought it was migraine, 5.4% mentioned daily headache, and 18.2% mentioned another type of headache. According to the IHS criteria the differentiation was somewhat different: 26.2% of the headache could be classified as tension-type headache and 15% as migraine. When the costs for lost labour days and loss of productivity as a result of all types of headache were accumulated, the economic loss was estimated at 18.933 US dollars in 4 weeks (for the group of responders). In conclusion, headache is related to a substantial economic loss; migraine is probably underestimated in a workplace setting.

Entities:  

Mesh:

Year:  2002        PMID: 11882058     DOI: 10.1046/j.1468-1331.2002.00355.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  15 in total

Review 1.  Aspirin for acute treatment of episodic tension-type headache in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Burden of tension-type headache.

Authors:  Marc E Lenaerts
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 4.  Treatment of tension-type headache: from old myths to modern concepts.

Authors:  P Barbanti; G Egeo; C Aurilia; L Fofi
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

5.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

Review 6.  Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults.

Authors:  Guy Stephens; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-06-16

Review 7.  A qualitative review of the psychometric properties and feasibility of electronic headache diaries for children and adults: where we are and where we need to go.

Authors:  Jennifer N Stinson; Anna Huguet; Patrick McGrath; Brittany Rosenbloom; Charlene Soobiah; Meghan White; Geraldine Coburn
Journal:  Pain Res Manag       Date:  2013 May-Jun       Impact factor: 3.037

Review 8.  Ketoprofen for episodic tension-type headache in adults.

Authors:  Lucy Veys; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-09-22

Review 9.  Diagnosis, epidemiology, and impact of tension-type headache.

Authors:  Rigmor Jensen
Journal:  Curr Pain Headache Rep       Date:  2003-12

Review 10.  Ibuprofen for acute treatment of episodic tension-type headache in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore; Lars Bendtsen
Journal:  Cochrane Database Syst Rev       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.